Dislocation risk following total hip replacement is declining with time and is associated with a number of surgical, hospital, and patient-related factors that are generally modifiable, UK researchers report.
Treatment with the interleukin-1 inhibitor anakinra improves both glycemic and inflammatory endpoints among patients with rheumatoid arthritis and type 2 diabetes, suggest findings from the TRACK trial.
Ustekinumab elicits a greater clinical response versus placebo in patients with psoriatic arthritis naïve to tumor necrosis factor inhibitors, regardless of prior conventional synthetic DMARD or methotrexate exposure, PSUMMIT 1 and PSUMMIT 2 study data show.
Almost 20 million people worldwide were living with rheumatoid arthritis in 2017, with over a million new cases diagnosed each year, according to estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study.
Comorbidity, Kellgren–Lawrence grade, superior or superolateral femoral head migration, and subchondral sclerosis may each predict progression among patients with hip osteoarthritis, show the results of a systematic review.
Rheumatoid arthritis patients aged 65 years or older experience a similar response to treatment with golimumab plus methotrexate compared with younger patients, suggests a post-hoc analysis of the GO-FURTHER trial.
Combining denosumab with high-dose rather than standard-dose teriparatide results in greater increases in spine and hip bone mineral density in postmenopausal women with osteoporosis, phase IV study data show.
Low-intensity warfarin treatment has not demonstrated noninferiority to standard-intensity warfarin for the prevention of venous thromboembolism among older people undergoing hip or knee replacement surgery in a randomized controlled trial.
The low-dose recombinant human interleukin IL-2 therapy aldesleukin has a favorable safety profile and may restore regulatory T-cell homeostasis in people with systemic lupus erythematosus, suggest findings from a proof-of-concept phase I/IIa clinical trial.
Adalimumab, used with or without concurrent methotrexate, appears to be well tolerated among children with polyarticular‐course juvenile idiopathic arthritis, 7-year data from the STRIVE registry show.